肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.
我们描述了一例继发性外周 T 细胞淋巴瘤（PTCL），其来源于一名携带致病性胚系 BLM p.L107Ffs*36 变异的复发或难治性 B 细胞淋巴瘤患者输注的 CD19/CD22-4-1BB-CD3-lenti 双特异性嵌合抗原受体（CAR）-T 细胞。
Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.
CART22.19 疗法在高危儿科人群中显示出良好的安全性特征和有前景的临床活性，其双靶向设计使 CD19 阴性白血病获得疾病控制。
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target
基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。
ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.
CD19 CAR-T 疗法在复发/难治性非霍奇金淋巴瘤（NHL）中已取得显著缓解。
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
我们观察到良好的疗效，9例患者中有8例（89%）达到可测量残留病灶阴性缓解。
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
非霍奇金淋巴瘤（NHL）是血液系统常见的恶性肿瘤，传统治疗对复发/难治性NHL（R/R NHL）患者疗效有限，尤其是弥漫大B细胞淋巴瘤（DLBCL）患者。
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
这些数据提示，通过共转导实现双靶向可能预防 CAR-T 细胞治疗后的抗原阴性复发。
Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
中位年龄为 59 岁（范围 27-83），46/52 例为 III/IV 期疾病，中位随访时间为 21.6 个月。
MEMBER ACCOUNT
登录成功会直接打开下一页。
